AbbVie Inc. 3Y Total Assets Growth (CAGR)

3Y Total Assets Growth (CAGR) of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including 3Y Total Assets Growth (CAGR) growth rates and interactive chart.


Highlights and Quick Summary

  • Annual 3Y Total Assets Growth (CAGR) for 2020 was 28.61% (a 173.26% increase from previous year)
  • Annual 3Y Total Assets Growth (CAGR) for 2019 was 10.47% (a 174.8% increase from previous year)
  • Annual 3Y Total Assets Growth (CAGR) for 2018 was 3.81% (a -89.71% decrease from previous year)
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical 3Y Total Assets Growth (CAGR) of AbbVie Inc.

Most recent 3Y Total Assets Growth (CAGR)of ABBV including historical data for past 10 years.

Interactive Chart of 3Y Total Assets Growth (CAGR) of AbbVie Inc.

AbbVie Inc. 3Y Total Assets Growth (CAGR) for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 28.61%
2019 10.47%
2018 3.81%
2017 37.03%
2016 31.3%
2015 25.24%
2014 12.12%
2013 11.37%
2012 0.0%

Business Profile of AbbVie Inc.

Sector: Healthcare
Industry: Drug Manufacturers—General
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.